RxDoctor Payments Data

Vivian Paskowski, APRN

Nurse Practitioner · Fernandina Beach, FLNPI 1376851915

Payments from drug & device makers

$596in general payments, 2019–2025

Across 18 payments — averaging $33.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$135
  • GSK$120
  • Lucid Diagnostics Inc.$58
  • Novo Nordisk$51
  • Inspire Medical Systems, Inc.$50
  • Boston Scientific$45
  • plus $137 from 5 others

What the payments were for

  • Food & beverage$596100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$596 in reported general payments places this provider in the 65th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$40,012
Medicare patients
104
Services billed
515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$45,867
FarxigaDapagliflozin Propanediol24$29,808
JardianceEmpagliflozin26$19,984
EliquisApixaban27$19,615
MounjaroTirzepatide17$17,977
RybelsusSemaglutide12$17,566
TrulicityDulaglutide13$13,819
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,250
Atorvastatin Calcium191$2,049
Gabapentin109$1,947
Albuterol Sulfate HfaAlbuterol Sulfate85$1,659
ValacyclovirValacyclovir Hcl19$1,658
Omeprazole76$1,577
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,531
Losartan Potassium93$1,223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$51$63,43354 claims
Boehringer IngelheimJardiance$26$19,98426 claims
AbbVieSynthroid$44$1,15227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Fernandina Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →